Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,556.37
(
-0.37%
)
US TECH 100
23,594.80
(
1.01%
)
Dow Jones
46,124.06
(
-0.18%
)
Brent Oil
95.45
(
-1.09%
)
Bitcoin
71,400.99
(
1.25%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

AlpineBV_Miller

Send PM Follow Ignore
Followers 54
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

AlpineBV_Miller

Re: biomaven0 post# 115097

Wednesday, 02/23/2011 2:40:12 AM

Wednesday, February 23, 2011 2:40:12 AM

Post# of 257275
I don't think the composite endpoint trial will have a survival endpoint. They seem to believe they can design a composite as a hard endpoint (i.e. not Subpart H) approval. They plan to do a survival trial, but it won't be the one that starts 2H-2011.

Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now